Abstract
Over the past decade, various liquid biopsy techniques have emerged as viable
alternatives to the analysis of traditional tissue biopsy samples. Such surrogate ‘biopsies’ offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on bloodbased
biomarkers, predominantly using plasma- derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non- blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non- blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various
technical aspects of non- blood ctDNA assay development. We also reflect on the settings in which non- blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use.
alternatives to the analysis of traditional tissue biopsy samples. Such surrogate ‘biopsies’ offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on bloodbased
biomarkers, predominantly using plasma- derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non- blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non- blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various
technical aspects of non- blood ctDNA assay development. We also reflect on the settings in which non- blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use.
| Original language | English |
|---|---|
| Journal | Nature Reviews Clinical Oncology |
| DOIs | |
| Publication status | Published - 1 Aug 2022 |
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre
